# Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

> **NCT04484012** · PHASE2 · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 36 (estimated)

## Conditions studied

- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma

## Interventions

- **DRUG:** Acalabrutinib
- **BIOLOGICAL:** CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes

## Key facts

- **NCT ID:** NCT04484012
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-12-31
- **Primary completion:** 2026-09-02
- **Final completion:** 2026-09-02
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-11-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04484012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04484012, "Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04484012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*